The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

It’s scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years," ...

In particular, they pointed to ivonescimab’s progression-free survival hazard ratio of 0.52 when paired with chemo. That ...

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Q. You’ve written about problems with low sodium levels due to blood pressure pills or even very low-sodium diets. Don’t ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

Repare Therapeutics Inc. (NASDAQ: RPTX) is one of the best Canadian stocks with huge upside potential. As May began, Repare ...

While heart disease has been the leading cause of death in the U.S. for over a century, the past 50 years have seen a ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to ...

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction.